Nutex Health director granted 823 RSUs

Nutex Health Inc. director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026 as equity compensation.

Rhea-AI Filing Summary

Nutex Health Inc. director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026 as equity compensation. Each RSU represents a contingent right to receive one share of common stock upon vesting. These RSUs vest 100% on April 23, 2027, with pro‑rata vesting if he leaves the company without cause during the vesting period. Following this award, Jaumot holds 1,426 RSUs directly. This is a compensation-related acquisition, not an open‑market stock purchase or sale.

Insider Trade Summary

Grant/Award: 823 shares

Grant/Award 1 txn

Insider Jaumot Frank E

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSUs)	823	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units (RSUs) — 1,426 contracts (Direct)

Footnotes (2)

1. F1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.
2. F2. On April 23, 2026, the Reporting Person was granted 823 RSUs, which vest 100% on April 23, 2027. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

Key Figures

RSUs granted: 823 RSUs RSUs after transaction: 1,426 RSUs Transaction price per share: $0.0000 +2 more

5 metrics

RSUs granted 823 RSUs Equity award on April 23, 2026

RSUs after transaction 1,426 RSUs Total directly held following grant

Transaction price per share $0.0000 Grant of RSUs, no cash paid by director

RSU vesting date April 23, 2027 100% vesting date for 823 RSUs

Underlying common shares 823 shares Each RSU equals one common share upon vesting

Key Terms

Restricted Stock Units (RSUs), contingent right, vesting, par value

4 terms

Restricted Stock Units (RSUs) financial

"The director was granted 823 Restricted Stock Units (RSUs) as compensation."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

contingent right financial

"Each RSU represents a contingent right to receive one share of common stock."

vesting financial

"The RSUs vest 100% on April 23, 2027, subject to continued service."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

par value financial

"Each RSU corresponds to common stock with $0.001 par value."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nutex Health (NUTX) report for Frank E. Jaumot?

Nutex Health reported that director Frank E. Jaumot received a grant of 823 Restricted Stock Units (RSUs) on April 23, 2026. This award is equity compensation and not an open-market stock purchase or sale.

How many RSUs were granted to the Nutex Health (NUTX) director in this Form 4?

The director received 823 RSUs, each representing a right to one Nutex Health common share upon vesting. This grant increased his directly held RSUs to a total of 1,426 after the transaction.

When do the newly granted Nutex Health (NUTX) RSUs vest for the director?

The 823 RSUs granted on April 23, 2026 vest 100% on April 23, 2027. The filing states vesting occurs entirely on that date, subject to continued service with the company during the vesting period.

What happens to the Nutex Health (NUTX) RSUs if the director leaves without cause?

If the director leaves Nutex Health without cause during the vesting period, the RSUs vest on a pro-rata basis. The prorated vesting reflects the actual time he remained in service with the company.

Does this Nutex Health (NUTX) Form 4 show a stock purchase or sale by the director?

No, the Form 4 shows a grant of RSUs as compensation, coded as an acquisition (A). It is not an open-market purchase or sale and involves no reported transaction price per share.

How many Nutex Health (NUTX) RSUs does the director hold after this grant?

After receiving the 823 RSU grant, the director holds 1,426 RSUs directly. Each RSU is a contingent right to receive one Nutex Health common share upon satisfaction of the vesting conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 02:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaumot Frank E

(Last) (First) (Middle)

1776 YORKTOWN STREET SUITE 700

C/O NUTEX HEALTH INC.

(Street)

HOUSTON TEXAS 77056

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Nutex Health Inc. [ NUTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSUs)	$0(1)	04/23/2026		A		823		04/23/2027(2)	04/23/2027(2)	Common Stock	823	$0(1)	1,426	D

Explanation of Responses:

1. Each RSU represents a contingence right to receive one share of the issuer's common stock, $0.001 par value, upon vesting.

2. On April 23, 2026, the Reporting Person was granted 823 RSUs, which vest 100% on April 23, 2027. If the Reporting Person leaves service with Company without cause, during the vesting period, the RSUs shall vest on a pro-rata basis for the actual time in service for the Company.

	/s/ Frank E. Jaumot	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)